Telmisartan

Telmisartan is an angiotensin II receptor blocker used to treat high blood pressure, commonly taken once daily in 20, 40, or 80 mg doses. It lowers blood pressure by blocking the action of angiotensin II, a hormone that narrows blood vessels and promotes sodium retention. One practical point that matters for patients is that telmisartan has a long duration of action, which helps provide 24-hour blood pressure control, including the early morning period when cardiovascular risk rises.

What it is

Telmisartan is a prescription medicine in the ARB class, short for angiotensin II receptor blockers. Brand names include Micardis and, in India, Telma among others. It is mainly used to treat hypertension and may also be used in some people to reduce cardiovascular risk when an ACE inhibitor is not suitable.

ARBs are often chosen when a person needs a blood pressure medicine that is effective, usually once daily, and less likely than ACE inhibitors to cause a dry cough. Telmisartan is available alone and in fixed-dose combinations, especially with amlodipine or hydrochlorothiazide, when one medicine is not enough to reach blood pressure targets.

A quick comparison:

Feature	Telmisartan
Drug class	Angiotensin II receptor blocker (ARB)
Common uses	High blood pressure; cardiovascular risk reduction in selected adults
Typical tablet strengths	20 mg, 40 mg, 80 mg
Usual schedule	Once daily
Common brands	Micardis, Telma

In India, telmisartan is widely prescribed in primary care and cardiology practice because hypertension is common and long-term adherence is easier with once-daily medicines. Real-world Indian data suggest it is frequently used in patients who also have diabetes or dyslipidemia, though prescribing should still be individualized.

How it works

Telmisartan blocks the AT1 receptor, the main receptor through which angiotensin II raises blood pressure. When this receptor is blocked:

1. Blood vessels relax and widen.
2. Aldosterone effects are reduced, so the body retains less sodium and water.
3. Blood pressure falls, which reduces strain on the heart and blood vessels.

Because telmisartan has a relatively long half-life compared with some other ARBs, its effect tends to last through the full day and night. This is one reason it has been studied for control of the early morning blood pressure surge, a time linked to higher rates of heart attack and stroke.

Telmisartan does not usually cause the bradykinin-related cough seen with ACE inhibitors. That can make it a useful alternative for people who developed cough on medicines such as ramipril or enalapril.

Evidence and uses

The main evidence-based use of telmisartan is hypertension. Clinical studies and reviews show that it lowers systolic and diastolic blood pressure and can provide sustained 24-hour control. A review in Vascular Health and Risk Management noted that telmisartan 80 mg controlled the early morning blood pressure surge more effectively than ramipril 5 to 10 mg in comparative studies.

A meta-analysis comparing telmisartan with losartan in adults with mild to moderate essential hypertension found stronger blood pressure reduction with telmisartan overall, although the exact benefit for an individual patient depends on dose, baseline blood pressure, other illnesses, and adherence.

Telmisartan is also used when a single drug is not enough. Combination treatment is common because many patients need more than one medicine to reach target blood pressure. Evidence supports fixed-dose combinations such as:

Combination	Why it may be used
Telmisartan + amlodipine	Adds vasodilation through a calcium channel blocker
Telmisartan + hydrochlorothiazide	Adds a diuretic effect

Studies of telmisartan/amlodipine single-pill combinations suggest they are effective and generally well tolerated for long-term blood pressure control. Single-pill combinations can also improve adherence by reducing pill burden.

Some guidelines and product labeling also include cardiovascular risk reduction in selected high-risk adults who cannot take an ACE inhibitor. This is not the same as using telmisartan for every person with hypertension, and the decision depends on the person's overall cardiovascular profile.

Evidence in Indian patients is mostly consistent with global data, but some Indian real-world studies are retrospective and industry-linked, so they are useful for practice patterns but not as strong as large independent randomized trials.

Safety and interactions

Telmisartan is generally well tolerated, but it can cause side effects and important drug interactions.

Common or notable side effects include:

• Dizziness, especially after starting treatment or increasing the dose
• Low blood pressure
• Increased blood potassium (hyperkalemia)
• Changes in kidney function, including a rise in creatinine

Important safety points:

• Pregnancy: Telmisartan should not be used during pregnancy because drugs that act on the renin-angiotensin system can harm the developing fetus.
• Kidney disease or dehydration: Risk of kidney injury is higher if a person is volume-depleted, has renal artery stenosis, or is taking other medicines that affect kidney blood flow.
• Potassium: Combining telmisartan with potassium supplements, potassium-containing salt substitutes, or potassium-sparing diuretics can raise potassium too much.

Key interactions include:

Drug or product	Why it matters
NSAIDs such as ibuprofen or diclofenac	May reduce blood pressure effect and increase kidney risk
Potassium supplements or salt substitutes	Can increase risk of hyperkalemia
Potassium-sparing diuretics	Additive potassium increase
Lithium	Lithium levels may rise
Other RAAS blockers, including ACE inhibitors or aliskiren	Higher risk of kidney problems, low blood pressure, and high potassium in some patients

People should not stop telmisartan on their own just because they feel well. High blood pressure often causes no symptoms, and the benefit comes from steady long-term control. Talk to a clinician or pharmacist before combining it with over-the-counter pain medicines, supplements, or herbal products.

When to see a clinician

Seek routine follow-up after starting telmisartan so blood pressure, kidney function, and potassium can be checked when appropriate. Contact a clinician sooner if you have fainting, severe dizziness, swelling, very low urine output, or symptoms that could suggest high potassium such as marked weakness or palpitations.

Get urgent care for chest pain, stroke symptoms, severe shortness of breath, or signs of a serious allergic reaction. If you become pregnant or are planning pregnancy, tell your clinician promptly because telmisartan usually needs to be changed to a safer alternative.

Limitations and open questions

Telmisartan is effective for many patients, but it is not the right choice for everyone. Blood pressure response varies, and many people need combination therapy plus lifestyle measures such as lower sodium intake, weight management, and regular physical activity.

Some comparative claims between telmisartan and other ARBs come from meta-analyses or older head-to-head studies rather than large modern outcome trials. Real-world studies from India add useful context, but retrospective designs can introduce bias. The strongest conclusion is that telmisartan is a well-established ARB for hypertension with good 24-hour control, while the exact advantage over other first-line options depends on the clinical setting, tolerability, cost, and patient preference.